<DOC>
	<DOCNO>NCT00381199</DOCNO>
	<brief_summary>Most chronic pain patient insomnia currently well-managed use exist medication . If find safely improve sleep chronic pain patient , nabilone could add treatment option available management fibromyalgia associate symptom . The principle hypothesis study nabilone dose 0.5-1mg efficacious amitriptyline dose 10-20mg , improve sleep quality patient fibromyalgia .</brief_summary>
	<brief_title>Nabilone Versus Amitriptyline Improving Quality Sleep Patients With Fibromyalgia</brief_title>
	<detailed_description />
	<mesh_term>Fibromyalgia</mesh_term>
	<mesh_term>Myofascial Pain Syndromes</mesh_term>
	<mesh_term>Sleep Initiation Maintenance Disorders</mesh_term>
	<mesh_term>Amitriptyline</mesh_term>
	<mesh_term>Dronabinol</mesh_term>
	<mesh_term>Amitriptyline , perphenazine drug combination</mesh_term>
	<mesh_term>Nabilone</mesh_term>
	<criteria>Patients age ≥18 year ; A diagnosis fibromyalgia accord American College Rheumatology classification criterion ( Wolfe F , Smythe HA , et al 1990 ) ; Suffering selfreported disturbed sleep ; Negative urine screen cannabinoids ; Women childbearing potential must agree use adequate contraception study 3 month study ; Ability attend research centre every second week approximately seven nine week able contact telephone study period ; Stable drug regimen 1 month prior randomization ; Normal liver ( AST &lt; 3x normal ) renal function ( serum creatinine &lt; 133µmol/L ) ; Haematocrit &gt; 38 % ; Negative serum bHCG ; Proficient English French ; Willing able give write informed consent ; Ability follow study protocol ( cognitive situational ) . Patients currently use cannabis cannabinoid tricyclic antidepressant ( TCA ) unable undergo 2 week washout period enter study ; Pain due cancer ; Unstable cardiac disease cardiac arrhythmia , cardiac failure , ischaemic heart disease and/or hypertension clinical history examination ; History psychotic disorder schizophrenia ; Known hypersensitivity cannabinoids , amitriptyline , relate tricyclic antidepressant ; Currently take unable stop take monoamine oxidase inhibitor ( twoweek washout period necessary subject take MAOIs ) ; History seizures/epilepsy ; Diagnosis glaucoma ; Urinary retention ; Pregnancy and/or breastfeed ; Participation clinical trial 30 day prior randomization ; A recent manic episode ( within past year ) ; Current suicidal ideation history suicide attempt</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2007</verification_date>
	<keyword>fibromyalgia</keyword>
	<keyword>cannabinoid</keyword>
	<keyword>chronic pain</keyword>
	<keyword>sleep</keyword>
	<keyword>insomnia</keyword>
	<keyword>diffuse widespread pain</keyword>
	<keyword>antidepressant</keyword>
</DOC>